13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details
Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05340985 (ClinicalTrials.gov) | July 2022 | 2/3/2022 | Investigating the Effects of Hydroxyvitamin D3 on Multiple Sclerosis | Investigating the Effects of Hydroxyvitamin D3 Versus Vitamin D3 on Clinical, and Radiologic Progress and Th17/Tregs Balance in MS Patients: A Randomized, Clinical Trial- a Pilot Study | Multiple Sclerosis, Relapsing-Remitting;Adult ALL;Vitamin D3 Deficiency | Dietary Supplement: 25(OH)D3;Dietary Supplement: vitamin D3 | Tehran University of Medical Sciences | Boston University | Not yet recruiting | 18 Years | 55 Years | All | 54 | Phase 4 | NULL |